StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research note released on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
NASDAQ:PULM opened at $2.12 on Wednesday. Pulmatrix has a 52-week low of $1.55 and a 52-week high of $2.75. The stock has a fifty day moving average of $2.09 and a 200 day moving average of $2.01. The firm has a market capitalization of $7.75 million, a price-to-earnings ratio of -0.88 and a beta of 1.00.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%. The business had revenue of $1.55 million for the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
See Also
- Five stocks we like better than Pulmatrix
- The Role Economic Reports Play in a Successful Investment Strategy
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- 3 Monster Growth Stocks to Buy Now
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- 10 Best Airline Stocks to Buy
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
